Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Each subject may be of either sex and of any race/ethnicity, and must be \>=6 and \<=10 years of age, with a diagnosis of primary hypercholesterolemia (heterozygous familial or nonfamilial) despite being on a lipid-lowering diet for at least 3 months with a LDL-C of \>159mg/dL~* Each subject's parent/guardian must be willing to give written informed consent on his/her behalf.~Exclusion Criteria:~Each subject must not:~* Have known hypersensitivity or any contraindication to ezetimibe.~* Have use of any investigational drugs within 30 days of study entry.~* Be a member or a family member of the personnel of the investigational or sponsor staff directly involved with this trial.~* Be a female of child-bearing potential who is pregnant, intends to become pregnant, or is nursing~* Have known congenital cardiac disorder.~* Have documented or laboratory values consistent with homozygous familial hypercholesterolemia (HoFH).~* Be known to be human immunodeficiency virus (HIV) positive.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe (Type: EXPERIMENTAL): Ezetimibe 10-mg tablet once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).